Petros Pharmaceuticals, Inc. 8-K

What Happened

• Petros Pharmaceuticals, Inc. filed an 8-K disclosing that its Board approved RSU grants effective January 2, 2026 (approved Jan 1, 2026) totaling 7,250,000 restricted stock units (RSUs).
• Recipients and amounts: Joshua Silverman (Chairman) 4,375,000 RSUs; Bruce Bernstein (director) 1,875,000 RSUs; Fady Boctor (President & Chief Commercial Officer) 500,000 RSUs; Wayne Walker (director) 500,000 RSUs. Each RSU represents the right to receive one share of common stock.

Key Details

• Grant Date: January 2, 2026 (Board approval on January 1, 2026).
• Vesting: 50% of each award vested on the Grant Date; remaining 50% vests six months later if the recipient continues to provide services.
• Total RSUs: 7,250,000 potential shares; awards were issued outside the Company’s 2020 Omnibus Incentive Compensation Plan and are governed by the Company’s standard RSU agreement.

Why It Matters

• These awards authorize up to 7.25 million additional shares if settled in stock, which could dilute existing shareholders if the RSUs are converted to shares.
• The immediate 50% vesting reduces risk of forfeiture for recipients and signals near-term compensation to key executives and directors; the remaining vesting ties additional benefit to continued service.
• Investors should view this as an equity compensation action (not a cash payout) intended to retain and reward leadership; the filing does not report departures, cash payments, or changes in corporate control.